Skip to content
Screener

Harmony Biosciences Holdings, Inc. HRMY Operating Cash Flow

Operating Cash Flow at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$408.2M-5.0%
Alkermes logo
AlkermesALKS
-$165.74M-268%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$20.7M+52.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$60.58M-146%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$21.24M-125%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$100.78M+57.6%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$2.26B+13.1%
Enterprise value$1.83B+12.9%
P/E15.5×+4.5×
P/S2.5×-0.1×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:16 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056720
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Prepaid expenses and other assets(2,996)(1,999)
Trade payables10,9073,715
Other liabilities(46,184)(5,456)
Net cash provided by operating activities27,76033,987
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities(178,995)(19,132)
Proceeds from maturities and sales of investment securities27,34921,622
Purchase of property and equipment—(128)

Item 1. Financial Statements

FAQ

What is Harmony Biosciences Holdings, Inc.'s operating cash flow?
Harmony Biosciences Holdings, Inc. (HRMY) reported operating cash flow of $27.76M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s operating cash flow changed year-over-year?
Harmony Biosciences Holdings, Inc.'s operating cash flow decreased by 18.3% year-over-year, from $33.99M to $27.76M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), Harmony Biosciences Holdings, Inc.'s operating cash flow has grown at a 37.1% compound annual growth rate (CAGR), from $98.56M to $348.2M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Harmony Biosciences Holdings, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude